The merger of Shire PLC and Takeda Pharmaceutical Co. Ltd., positions the combined firm to join the ranks of the top 10 pharmaceutical firms – and will bring with it the attendant pressures on reviews and approvals.
The companies said the transformative tie-up – effectively a merger given Shire's larger size and current market cap – will create a group with leading positions in rare diseases and plasma-derivatives, along with complementary strengths in